In cancer, mucins are aberrantly O-glycosylated and consequently, they express tumor-associated antigens such as the Tn determinant (α-GalNAc-O-Ser/Thr). They also exhibit a different pattern of expression as compared to normal tissues. In particular, MUC6, which is normally expressed only in gastric tissues, has been detected in intestinal, pulmonary, colorectal and breast carcinomas. Recently, we have shown that the MCF7 breast cancer cell line expresses MUC6-Tn glycoproteins in vivo.
INTRODUCTION
Malignant cells selectively express on their surface molecules that have functional importance in cell adhesion, invasion and metastasis. Some of these tumor-associated structures are the result of a blockage in the glycosylation pathway. In particular, the incomplete elongation of O-glycan saccharide chains leads to the expression of shorter carbohydrate structures such as Tn, sialyl-Tn or TF antigens (Hollingsworth and Swanson 2004) . The Tn antigen, defined as a GalNAc unit α-linked to a serine or threonine residue (α-GalNAc-O-Ser/Thr), is one of the most specific human cancer-associated structures. Tn is detected in about 90% of human carcinomas (Springer 1984 ) and its expression is correlated to carcinoma aggressiveness (Springer 1997) . Moreover, under appropriate conditions, Tn is capable of inducing a strong immune response in mice and non human primates, the resulting antibodies being capable of recognizing human cancer cells (Lo-Man et al. 2001 , Lo-Man et al. 2004 ).
This O-linked epitope is usually expressed on mucins as their carbohydrate core structure (Hollingsworth and Swanson 2004) . Mucins are high molecular weight O-glycosylated proteins (50-80% of their mass is due to O-linked carbohydrate chains) that participate in protection, lubrication and acid resistance of the epithelial surface (Gendler and Spicer 1995) . To date, different mucins have been identified and numbered in chronological order of their description (MUC1-MUC20) (Chen et al. such, they may be used as potential targets for immunotherapy (Agrawal et al. 1998 , Apostolopoulos et al. 1996 . In particular, MUC1 is undergoing several clinical trials as anti-cancer vaccine (Finn et al. 1995 , Gilewski et al. 2000 .
MUC6 was first isolated from a human stomach library (Toribara et al. 1993) and it is expressed at high levels in the normal stomach and gall bladder with weaker expression in the terminal ileum, right colon and in the endocervix (De Bolos et al. 1995 , Ho et al. 1995 , Reis et al. 2000 , Toribara et al. 1993 ). MUC6 has a tandem repeat unit of 169 amino acids (507 bp each) (Toribara et al. 1993) and Southern blot analyses of the shortest MUC6 alleles indicate that they contain at least 15 repeat units (Vinall et al. 1998) . Although the whole MUC6 gene was localized and identified, a full length cDNA has not been completely sequenced yet (Rousseau et al. 2004) . In addition to its normal expression in gastric tissues, MUC6 has been detected in Barret adenocarcinoma and metasplasia (Guillem et al. 2000) , in intestinal adenoma and carcinoma (Guillem et al. 2000) , in pulmonary carcinoma (Hamamoto et al. 2005 , Nishiumi et al. 2003 , in colorectal polyps (Bartman et al. 1999) and in breast carcinoma (De Bolos et al. 1995 , Pereira et al. 2001 , while it is not expressed in the respective normal tissues. In some cases, MUC6 expression has been reported to be correlated to degrees of histopathology related to malignant potential (Bartman et al. 1999 , Hamamoto et al. 2005 , Nishiumi et al. 2003 . We have recently shown that MUC6 is aberrantly glycosylated in MCF7 breast cancer cells since it contains the Tn antigen (Freire et al. 2005) . Several studies have shown that the carbohydrate structures on mucins (including the core Tn antigen) may be essential for the definition of the tumorassociated structures (Grinstead et al. 2003 , von Mensdorff-Pouilly et al. 2005 . Therefore, Tn-MUC6 glycoconjugates represent attractive targets to be used in cancer immunotherapy. A specific anti-Tn antibody response should target cancer cells through the Tn antigen, which is expressed on their surface. Furthermore, the activation of mucin-specific cytotoxic T lymphocytes should be favored through the up-take of soluble MUC6-Tn immune complexes by Fc receptors on dendritic cells (Amigorena and Bonnerot 1999) .
In order to further develop anti-cancer vaccines based on the Tn antigen, we established an in vitro enzymatic method for the preparation of MUC6-Tn glycoconjugates. To this end, we performed the characterized by SELDI-TOF MS ( Figures 2D and 2E) . In all assays, the starting protein was totally converted into glycoconjugates. The SELDI-TOF MS profiles showed different GalNAc glycosylation levels of the protein (major peak ± 3 GalNAc) (Figures 2D and 2E) . A similar polydispersity was observed on the crude mixtures and on the purified glycoconjugates, independently of the protein acceptor and of the enzyme source used (data not shown).
Physico-chemical characterization of the synthesized glycoconjugates
Four different MUC6 glycoconjugates were synthesized by this enzymatic transglycosylation and purified by Ni-NTA agarose and HPLC. Then, they were subjected to SDS-PAGE analysis (Figure 3) confirming the presence of purified glycoproteins at the expected molecular weights. The MUC6 glycoproteins presented different Tn content depending on the mucin backbone and on the different ppGalNAc-T source used (Table I) . When the MCF7 breast cancer cell extract was used, an average of 54-58% of potential O-glycosylation sites was glycosylated, representing 30-32% of the total molecular mass, independently of the mucin used as acceptor. A different Tn density was obtained when the mucin proteins were glycosylated by the purified bppGalNAc-T1. MUC6-2 was less 4C-D shows that both anti-Tn mAbs, although at different rates, recognized the MUC6-Tn glycoconjugates, whereas the corresponding non-glycosylated MUC6 proteins were not recognized.
The anti-Tn mAb 83D4 similarly recognized MUC6-1 and MUC6-2 glycoconjugates ( Figure 4C) while MLS128 showed less reactivity with the MUC6-2:Tn(T1) glycoconjugate, which was the one with the lowest Tn density ( Figure 4D ). All glyco-and non-glycosylated MUC6 proteins were differently recognized by the anti-MUC6 serum ( Figure 4E ). The non-glycosylated MUC6 proteins were slightly more reactive than the MUC6-Tn glycoconjugates, probably due to the lack of accessibility to the protein backbone in highly glycosylated proteins.
MUC6-2:Tn(MCF7) glycoconjugate induces antibodies that recognize tumor cells
The immunogenicity of one of the MUC6-Tn glycoconjugates was studied. BALB/c mice were immunized with the MUC6-2:Tn(MCF7) glycoconjugate, or with the non-glycosylated MUC6-2 protein in alum plus CpG, and sera were tested for their capacity of recognizing the human tumor cell line Jurkat ( Figure 5 ). Control mice received only CpG in alum. It is worth noting that all MUC6 glycoproteins showed very low levels of endotoxins (<2 EU/mg of protein). Immunization with the MUC6-2:Tn(MCF7) glycoconjugate, but not with the non-glycosylated MUC6-2 protein, induced IgG antibodies that recognized the Jurkat human tumor cell line ( Figure 5A ). In order to confirm that these antibodies recognized the Tn antigen on these cells, we carried out inhibition assays using either asialo-OSM (carrying the Tn antigen) or deglycosylated-OSM. As shown in Figure 5B , only asialo-OSM inhibited the recognition of the Jurkat cells by sera obtained after immunization with MUC6-2:Tn(MCF7) and by the anti-Tn mAb 83D4 (used as control). In contrast, the binding of an anti-CD4 antibody to Jurkat cells was not affected in either of the two cases ( Figure 5B ). These experiments clearly show that MUC6-2:Tn(MCF7) can induce anti-Tn antibodies that recognize Tn+ tumor cells.
DISCUSSION
The aim of cancer immunotherapy is to elicit protective immunity against cancer cells without causing collateral autoimmune damage. One approach is based on the induction of tumor-specific immune responses by cancer-associated antigens. To this end, mucins can be used as immunogens in vaccines designed to elicit therapeutic anti-tumor immunity.
Cancer-associated changes occur not only in mucin protein expression between normal and abnormal tissues, but also in the pattern of O-glycosylation that distinguishes cancer mucins from normal mucins. Indeed, mucins are normally highly glycosylated and thus, the antigenic peptide core is physically inaccessible to the immune system, and particularly to antibodies. However, in tumor cells, they present cancer-associated truncation of O-linked carbohydrate chains creating the tumor-specific TF, Tn and sialyl-Tn antigens (Hollingsworth and Swanson 2004) . This suggests that such glycosylated mucins can be used as targets for treatment of specific cancers.
Various vaccines based on the Tn structure have been developed and tested in preclinical or clinical models. Desialylated ovine submaxillary mucin (expressing high Tn levels) (Singhal et al. 1991) and Tn protein conjugates (Kuduk et al. 1998 , Longenecker et al. 1987 , Toyokuni et al. 1994 ) induced high Tn-specific antibody titers in mice resulting in protection against tumor challenge. In humans, desialylated red blood cells (rich in Tn and T antigens) allowed a protection against recurrence of advanced breast cancer (Springer et al. 1993) . More recently, a clinical trial with a Tn-protein conjugate resulted in an anti-tumor effect as determined by a decline in the PSA slope (Slovin et al. 2003) . We also reported the preparation of a fully synthetic vaccine based on the Tn antigen, the MAG for Multiple Antigenic Glycopeptide (Bay et al. 1997) . MAG:Tn vaccines are capable of inducing, in mice and in non-human primates, strong tumor-specific anti-Tn antibodies that can mediate antibodydependent cell cytotoxicity against human tumor cells (Lo- Man et al. 2004) . However, large scale preparation of such conjugates is limited by the complexity of the whole synthesis process.
To further extend the scope of our approach to clinical trials, we propose to enzymatically attach the Tn antigen to a mucin core protein. To this end, we chose the MUC6 mucin which is aberrantly expressed in different cancers and may constitute a target antigen itself. Indeed, MUC6 has been detected in intestinal, pulmonary, colonic and mammary adenocarcinomas while it is not expressed by the respective normal tissues (Bartman et al. 1999 , De Bolos et al. 1995 , Guillem et al. 2000 , Hamamoto et al. 2005 , Nishiumi et al. 2003 , Pereira et al. 2001 . Furthermore, our preliminary data suggest that MUC6 carries the Tn antigen in MCF7 breast cancer cells (Freire et al. 2005) .
In the present work, we describe the enzymatic synthesis of Tn-expressing MUC6 glycoconjugates. In order to produce high amounts of MUC6-Tn glycoconjugates, we performed the GalNAc transfer to a recombinant MUC6 protein expressed in E. coli by using ppGalNAc-Ts. This large family of enzymes catalyzes in vivo the linking of a GalNAc residue to serine or threonine (i.e. the synthesis of the Tn antigen). To date, fifteen ppGalNAc-Ts have been identified in mammals, and functional profiles of each member of the family have been established showing that these enzymes have not only different substrate specificities, but also specific tissue-expression patterns (Cheng et al. 2004 , Ten Hagen et al. 2003 .
Glycosyltransferases have been extensively used as tools to perform transglycosylation reactions since (Takeuchi et al. 2002 ) or MUC2 (Irimura et al. 1999 , Kato et al. 2001 ) and they were performed at the analytical scale (0.1-10 µg range). Interestingly, however, recombinant ppGalNAc-T2 and -T4 allowed the preparation of MUC1-Tn glycopeptides which were used for immunization purposes (Kagan et al. 2005) . In addition, a comprehensive study about the synthesis of MUC1-Tn peptides using ppGalNAc-T2, -T4 and -T11 was published during the course of examination of this manuscript (Sorensen et al. 2005) .
In the present study, we used either ppGalNAc-Ts from cancer cell extracts or purified recombinant bovine ppGalNAc-T1 to achieve the maximal GalNAc transfer to the serine and threonine residues of a MUC6 recombinant protein. These two ppGalNAc-T sources were chosen for two reasons. On the one hand, breast cancer cell extracts were used in order to better mimic the in vivo O-glycosylation sites of MUC6 in cancer cells. On the other hand, the recombinant bppGalNAc-T1 has a very broad specificity and the in vitro glycosylation assays using a purified recombinant protein are expected to give more reproducible results and to allow easier purification. Indeed, the product yield obtained using both ppGalNAc-T sources was different, being higher when using the recombinant bppGalNAc-T1 (59-69 % for bppGalNAc-T1 versus 25-34 % for MCF7 extracts). This difference is due to an additional step needed to purify the MUC6-Tn glycoconjugates from the reaction mixture containing MCF7 cell extract.
Although significant progress has recently been made in the synthesis of glycoconjugates, the access to this type of macromolecules remains very difficult, particularly when large quantities are required.
To our knowledge, this is the first time that a Tn-glycosylated recombinant protein is obtained in semipreparative amounts, by the use of ppGalNAc-Ts. By selecting the best conditions for maximal GalNAc transfer, we obtained MUC6 glycoconjugates carrying high densities of Tn antigen. These different Tn densities (54 GalNAc for MUC6-1:Tn(T1), 49 GalNAc for MUC6-1:Tn(MCF7), 20
GalNAc for MUC6-2:Tn(T1) and 26 GalNAc for MUC6-2:Tn(MCF7)) are the result of independent and reproducible experiments. Depending on the enzyme source, we produced glycoconjugates with different Tn levels. This could be explained by the specificity of ppGalNAc-Ts (not all threonine and serine residues are recognized by one ppGalNAc-T) (Ten Hagen et al. 2003) .
We also studied the glycosylation of two MUC6 recombinant proteins of different size (203 aa for MUC6-1 and 119 aa for MUC6-2), in order to evaluate if the GalNAc transfer is influenced by the length of the protein. When using a recombinant bppGalNAc-T1, we obtained an average of 54 and 20 incorporated GalNAc residues out of 85 and 48 potential O-glycosylation sites (total number of Thr and Ser residues) for MUC6-1 and MUC6-2 respectively, representing 64% and 42 % of Oglycosylation sites approximately. Structural studies would be necessary to determine whether these distinct glycosylation rates are due to a lack of accessibility of bppGalNAc-T1 for the acceptor sites in the mucin protein.
Of primary importance in the design of vaccines against cancer is that the antigen in the vaccine mimics the antigen on the tumor. In order to synthesize structures close to the native Tn clusters present in cancer cells, we also performed the GalNAc transfer using MCF7 breast cancer cell extracts, which may express various ppGalNAc-T isoforms, as already shown on other human cancer cell lines (Freire et al. 2005 , Mandel et al. 1999 , Marcos et al. 2003 . In this case, similar GalNAc density was obtained, being 49 for MUC6-1 and 26 for MUC6-2, representing 58% and 54%, respectively, of potential O-glycosylation sites. Thus, the degree of glycosylation obtained with the purified recombinant bppGalNAc-T1 and MCF7 cell extracts is different and, surprisingly, the Tn density is not necessarly higher in the latter case. This could be explained by the presence of different ppGalNAc-Ts in the cell extract, which act in a coordinate and sequential manner, and may contribute positively or negatively to the overall glycosylation of the protein.
Most of anti-Tn antibodies raised against cancer cells or tissues recognize groups of adjacent Tn epitopes usually called Tn clusters. Indeed, 83D4 and MLS128 anti-Tn mAbs require the presence of at least two consecutive Tn residues for substrate recognition (Nakada et al. 1993 , Osinaga et al. 2000 . Taking into account that 2/3 of the Thr and Ser residues in MUC6-1 and MUC6-2 are arranged in clusters it is highly probable that most of the Tn antigens will be presented, at least, as clusters of two Tn. The potential relevance of the MUC6-Tn glycoconjugates for tumor immunotherapy is evidenced by the analysis of their antigenicity. Indeed, the Tn antigen on MUC6 was recognized by Tn-specific monoclonal antibodies such as MLS128 and 83D4 and confirms the presence of Tn clusters. Analyses of the O-glycosylation in MUC6 proteins in order to determine the glycosylation sites in the different MUC6-Tn glycoconjugates are in progress.
As an example, we have also shown that one of the MUC6-Tn glycoconjugates is immunogenic.
Indeed, MUC6-2:Tn(MCF7) induced IgG antibodies in mice, which were capable of recognizing human tumor cells through a Tn-dependent mechanism. To our knowledge, this is the first work reporting the induction of human tumor cell-specific antibodies after immunization with a mucin derived protein carrying the Tn antigen, without a protein carrier. Indeed, the mucin-derived glycopeptides used so far as immunogens have been conjugated to KLH (Kagan et al. 2005 , Sorensen et al. 2005 . Such conjugates have limitations regarding their application for anti-cancer immunotherapy in humans. The immune response to the carrier molecule results in a low level of the desired antibodies as compared to the total amount of antibodies produced. This may lead to carrierinduced suppression of the immune response directed against the haptenic molecule (Schutze et al. 1985) . Furthermore, contrary to KLH conjugates, the structure and the composition of the MUC6-Tn vaccine can be determined by mass spectrometry. This feature is essential to meet the requirements of regulatory bodies for approval in humans.
In conclusion, the transglycosylation method of a recombinant mucin protein presented here is very convenient and effective since 100% of the starting protein was converted into glycosylated species.
Furthermore, a high glycosylation ratio is achieved. The ability to produce recombinant MUC6 with tumor-relevant glycoforms in large amounts is unique and will be extremely valuable for preclinical, immunological and tumor-protection studies. The anti-tumor potency of MUC6-Tn glycoconjugates is currently underway.
MATERIALS AND METHODS

MUC6 cloning and expression in E. coli
A cDNA clone containing one tandem repeat of human MUC6 was isolated from total cDNA of MCF7 breast cancer cells by RT-PCR and cloned into pGem-T (Promega, France). The PCR products were designed to encode one tandem repeat of human MUC6 (MUC6-1, 169 amino acids) or a half tandem repeat (MUC6-2, 87 amino acids) that were amplified with Pfu DNA polymerase and the primers MUC6-F, 5'-cgggatccTCCACCTCCTTGGTGACT-3' and MUC6-1R, 5'-ggaagcttTTAGAAAGGTGGAACGT G-3' (for MUC6-1) or MUC6-2R 5'-ggaagcttATTAGGATGGTGTGTGGA-3' (for MUC6-2) (lowercase characters indicate restriction sites for BamHI and HindIII in the forward and reverse primers, respectively). Following digestion with BamHI and HindIII, each product was cloned into the pET28a(+) vector (Novagen, Fontenay-sous-Bois, France), so as to encode for a protein carrying a six-histidine tail at the N-terminus. E. coli DH5α transformants were selected on LB plates containing 50 μg/ml kanamycin and the positive clones were confirmed by PCR and sequencing. Plasmids were purified from selected clones and used to transform E. coli BLi5 chemically competent cells. The recombinants were expressed in E. coli Bli5 by induction with 1 mM IPTG and purified over Ni 2+ -nitriloacetic acid columns under denaturing conditions according to the manufacturer's (Qiagen, Germany) instructions. MUC6-1 protein was further purified by HPLC using a Perkin-Elmer pump system with an UV detector at 230 nm. The column was a Symmetry 300™ C18 (5 µm, 300 Å, 3.9 x 250 mm) (Waters, France). Elution was carried out with a linear gradient of 10-60% acetonitrile in 0.1% trifluoracetic acid in water at a flow rate of 1 mL/min (over 30 min). The MUC6 proteins were charaterized by amino acid analysis (AAA) and SELDI-TOF MS. These analyses, together with a N-terminal sequencing, showed that both proteins lack the Nterminal methionine residue.
Breast cancer cell line extract
Breast cancer cell line MCF7 was grown to 90% confluence in Dulbecco's modified Eagle's medium (Life Technologies, Inc., Cergy Pontoise, France) with 10% fetal bovine serum, 1 mM pyruvate, 2 mM glutamine and 5% CO 2 at 37°C. After trypsinization, cells were washed three times with phosphate-buffered saline (PBS), resuspended in 250 mM sucrose and homogeneized. Cells were then centrifuged at 3,000 g for 10 min at 4°C. The resulting supernatant was again centrifuged at 100,000 g for 1 h at 4°C. The pellet was resuspended in 0.1 M imidazole pH 7.2 and 0.1% Triton X-100. The cell extract was aliquoted and stored at -80°C. Protein concentration was determined by the BCA method (Sigma Chemical Co., St Louis, MO).
Recombinant bovine ppGalNAc-T1
A soluble form of the bovine ppGalNAc-T1 (bppGalNAc-T1) was expressed in the yeast Pichia pastoris KM71H strain (Invitrogen, Cergy Pontoise, France) and purified from the culture supernatant.
The cDNA coding region for the soluble form of the bppGalNAc-T1 (from amino acids 52 to 559) was introduced in 3' of the α-factor sequence signal coding region of a pPICZαA expression vector (Invitrogen) modified to introduce a N-terminal 6His-tag and a C-terminal FLAG-tag. The KM71H strain was made competent using the Pichia EasyComp™ kit (Invitrogen, Cergy Pontoise, France) and transformed according to the manufacturer's instructions. After 120 h of induction in 0.5% methanol, the secreted bppGalNAc-T1 was purified on Ni-NTA-agarose (Qiagen, Hilden, Germany) as described (Duclos et al. 2004) . Fractions containing enzymatic activity were pooled and dialyzed against ultrapure water, the protein was freeze-dried and stored at -20°C until use. The specific activity of the recombinant bppGalNAc-T1 was tested as previously described (Duclos et al. 2004 ) and estimated to 3 U/mg protein (1 unit transfers 1 µmole of GalNAc per min at 37°C to the acceptor peptide [STP] 5 ).
In vitro GalNAc transfer to MUC6 proteins
Using MCF7 extracts
Optimal conditions for in vitro glycosylation of both MUC6 proteins were selected after testing different conditions assays in an analytical scale and characterizing the resulting glycoproteins by SELDI-TOF MS (Ciphergen Biosystems, California) as described separately (Freire et al. 2006 ).
Briefly, a microsome extract of MCF7 breast cancer cells was incubated at 37ºC with UDP-GalNAc and purified MUC6-1 or MUC6-2 in 50 mM imidazole pH 7.2 containing 15 mM MnCl 2 and 0.1%
Triton-X100. Aliquots were taken at different times and frozen at -20°C. IMAC30 chip array surfaces were activated with 100 mM NiCl 2 at room temperature for 15 minutes and then washed with water and PBS. Spots were incubated with the crude glycosylation mix aliquots for 40 minutes at room temperature using the bio-processor adaptor, and then washed with 0.1% Triton-X100 in PBS (2 x 5 min), PBS (3 x 2 min) and 5 mM HEPES (2 x 5 min). Chips were then read in the instrument (Ciphergen ProteinChip Reader, PBS II), and each array spot was laser-sampled. Spectra were treated using the Ciphergen ProteinChip software 3.2.1.
As a result, the following conditions were chosen and used for semi-preparative scale glycosylation transfer assays. Purified MUC6-1 or MUC6-2 (40-80 µM) was incubated with MCF7 extract (6 µg protein/µg mucin) and UDP-GalNAc (2 equivalents per Thr/Ser equivalent in mucin glycoproteins) in 50 mM imidazole pH 7.2 containing 50 mM MnCl 2 and 0.1% Triton-X100 at 37°C. After 24 hourincubation, the same amounts of MCF7 extract and UDP-GalNAc were added and incubated for another 24 h. The resulting MUC6-1:Tn or MUC6-2:Tn were purified using Ni-NTA-agarose (Qiagen, Hilden, Germany) and then subjected to reversed phase HPLC using a Perkin-Elmer pump system with an UV detector at 230 nm. The column was a Symmetry 300™ C18 (5 µm, 300 Å, 3.9 x 250 mm) (Waters, France). Elution was carried out with a linear gradient of 10-60% acetonitrile in 0.1% trifluoracetic acid in water at a flow rate of 1 mL/min (over 30 min). The peak was collected and then lyophilized. The MUC6-1:Tn and MUC6-2:Tn glycoproteins were characterized by AAA and mass spectrometry.
Using bppGalNAc-T1
Optimal semi-preparative optimal conditions of GalNAc transfer using bppGalNAc-T1 were set up using the Ciphergen® technology as described for the MCF7 extracts. MUC6-1 or MUC6-2 purified protein (40-80 µM) was incubated with UDP-GalNAc (2 equivalents per Thr/Ser equivalent in mucin glycoproteins) and bppGalNAc-T1 (0.1 µg/µg mucin) in 50 mM MES, pH 6.5 containing 15 mM MnCl 2 for 24 h at 37°C. The resulting MUC6-1:Tn or MUC6-2:Tn was directly subjected to reverse phase HPLC and purified as explained above. The peak was collected, lyophilized and characterized by AAA and mass spectrometry.
Antibodies
The mAb 83D4 (IgM) (kindly given by E. Osinaga), which recognizes specifically the Tn antigen (Osinaga et al. 2000) , was produced from a mouse immunized with cell suspensions obtained from formalin-fixed paraffin-embedded sections of an invasive human breast cancer (Pancino et al. 1990 ).
It was then precipitated from ascitic fluids by dialysis against demineralized water at 4°C, dissolved in a small volume of 0.5 M NaCl in PBS, and purified by gel-filtration chromatography on Sephacryl S-
200.
The anti-Tn mAb MLS128 (IgG 1 ), kindly given by H. Nakada, was obtained from a mouse immunized with human colonic cancer cells (LS180) (Numata et al. 1990 ) and purified by affinity GalNAc transfer into MUC6 proteins and GalNAc number determination. The transglycosylation reaction (A) was performed either with MUC6-1 purified mucin (3 mg, 0.14 µmoles) and UDPGalNAc (7.8 mg, 11.5 µmoles) using bppGalNAc-T1 (300 µg), or with MUC6-2 purified mucin (1 mg, 0.082 µmoles) and UDP-GalNAc (3.2 mg, 4.92 µmoles in two times) using MCF7 cell extracts (12 mg in two times). The MUC6-1:Tn(T1) glycoprotein was directly analyzed by HPLC (B). The MUC6-2:Tn(MCF7) glycoprotein was purified using Ni-NTA agarose, analyzed by HPLC (C). After purification by HPLC, MUC6-1:Tn(T1) (D) and MUC6-2:Tn(MCF7) (E) were analyzed by SELDI-TOF MS. Each peak is labelled with the mass/charge (m/z) value in daltons. The corresponding number of incorporated GalNAc units is indicated in brackets. 
ELISA (C-E).
Glycoconjugates were separated in a 13% SDS-PAGE and transferred onto nitrocellulose sheets. An The equivalent amount is expressed as compared to the total potential O-glycosylation sites (i.e. total serine and threonine residues) 2 Isolated product yields refers to the obtained yield after the glycosylation reaction and purification of the resulting glycoprotein. MUC6-Tn glycoconjugates were tested for the endotoxin levels, and found to be lower than 2 EU/mg of glycoprotein in all cases 3
The average molecular mass and GalNAc number of the glycoconjugate were calculated from the medium peak 4
The % of obtained glycosylated sites was calculated taking into account the obtained GalNAc number for each glycoconjugate as compared to the total number of serine and threonine residues in the proteins (85 for MUC6-1 and 48 for MUC6-2) (100 %)
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